1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

ATMP Makers Encouraged To Consult Local Regulators On Compliance with EU GMP Guidelines

 
• By Eliza Slawther

Cell and gene therapy manufacturers based in Europe should speak to local regulators to understand how to demonstrate compliance with EU-level good manufacturing practice guidelines, as each country will apply the rules differently, an expert explains.

GMP logo
Compliance with GMP is crucial for ATMP manufacturers (Shutterstock)

An increasing number of advanced therapy medicinal products (ATMPs) are entering the market, with the world’s first gene editing therapy, Vertex Pharmaceuticals/CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel), gaining both UK and EU approval within the past year.

Compliance with good manufacturing practice (GMP) guidelines is crucial for ATMP manufacturers, but meeting expectations will require companies to understand...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Geography

Business Background Of New CDER Director George Tidmarsh

 
• By Bridget Silverman

George Tidmarsh has extensive experience in the biopharmaceutical industry and led several drugs to FDA approval.

‘Prescription Drugs Are Not Golf Balls’: FTC/DoJ Solicit Clashing Opinions On Patents

 
• By Urtė Fultinavičiūtė

Innovator drug advocates argued that the number of patents asserted by industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

US FDA Could Seek Stronger Warnings On SSRI Antidepressant Risks During Pregnancy

 
• By Sue Sutter

Testimony during a July 21 ‘expert panel’ could help justify stronger warnings across the class about potential adverse effects on mother and baby. Panelists ranged from clinicians who said depression during pregnancy should be treated, to those who said sadness has been “medicalized."